SMC4 (structural maintenance of chr3 4) is a central ATP-binding component of the condensin complex essential for mitotic chromosome 3 and genomic stability 1. Beyond its canonical role in introducing positive supercoils into DNA and facilitating sister chr3 segregation, SMC4 has emerged as a multifunctional oncogenic regulator with significant clinical implications. Mechanistically, SMC4 promotes tumorigenesis through multiple pathways. In prostate cancer, SMC4 interacts with GLUT1 to activate the Rheb/mTOR pathway, enhancing glycolysis and cell proliferation 2. In colorectal cancer, SMC4 acts as a co-activator of PGAM1 transcription while promoting lactate-mediated ABC transporter expression, conferring chemotherapy resistance 3. In hepatocellular carcinoma, the USP39/SMC4 axis regulates 5-FU resistance potentially through TIAL1 and ZNF207 interactions 4. Notably, in triple-negative breast cancer, SMC4 suppresses cGAS-STING-mediated interferon signaling while upregulating PD-L1, driving immune evasion 5. Clinically, elevated SMC4 expression correlates with poor prognosis across multiple cancers including sarcoma, gastric, breast, liver, ovarian, and colon adenocarcinoma 67. SMC4 also associates with clonal hematopoiesis and altered hematopoietic stem cell self-renewal 8. These findings establish SMC4 as a potential prognostic biomarker and therapeutic target for cancer treatment.